BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30066203)

  • 1. Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.
    Nortunen M; Huhta H; Helminen O; Parkkila S; Kauppila JH; Karttunen TJ; Saarnio J
    Virchows Arch; 2018 Nov; 473(5):567-575. PubMed ID: 30066203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker.
    Turner JR; Odze RD; Crum CP; Resnick MB
    Hum Pathol; 1997 Jun; 28(6):740-4. PubMed ID: 9191010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic Anhydrases II and IX in Non-ampullary Duodenal Adenomas and Adenocarcinoma.
    Nortunen M; Parkkila S; Saarnio J; Huhta H; Karttunen TJ
    J Histochem Cytochem; 2021 Nov; 69(11):677-690. PubMed ID: 34636283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumorigenesis markers BMI1, MCM4 and MCM7.
    Huber AR; Tan D; Sun J; Dean D; Wu T; Zhou Z
    BMC Gastroenterol; 2015 Jul; 15():80. PubMed ID: 26156831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
    Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
    Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.
    Fisher OM; Levert-Mignon AJ; Lord SJ; Botelho NK; Freeman AK; Thomas ML; Falkenback D; Wettstein A; Whiteman DC; Bobryshev YV; Lord RV
    Ann Surg Oncol; 2015 Jul; 22(7):2431-8. PubMed ID: 25348778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
    Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
    Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
    Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
    Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
    Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
    Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
    Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
    Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear localization of Toll-like receptor 5 in Barrett's esophagus and esophageal adenocarcinoma is associated with metastatic behavior.
    Helminen O; Huhta H; Leppänen J; Kauppila JH; Takala H; Lehenkari PP; Saarnio J; Karttunen TJ
    Virchows Arch; 2016 Oct; 469(4):465-70. PubMed ID: 27392931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time gated fluorescence spectroscopy in Barrett's oesophagus.
    Ortner MA; Ebert B; Hein E; Zumbusch K; Nolte D; Sukowski U; Weber-Eibel J; Fleige B; Dietel M; Stolte M; Oberhuber G; Porschen R; Klump B; Hörtnagl H; Lochs H; Rinneberg H
    Gut; 2003 Jan; 52(1):28-33. PubMed ID: 12477755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
    Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
    Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.